Centocor Remicade approval
Executive Summary
Centocor's Remicade (infliximab) sBLA approved June 28 for "inducing and maintaining clinical remission in patients with moderately to severely active Crohn's disease." The supplemental application was submitted Dec. 28, 2001 and received a priority review. Remicade was approved for "reducing signs and symptoms" of Crohn's disease in August 1998...